Webinars Back to resource centre 11 January 2023 Virtual clinical trials: What have we learned in the era of Covid-19? Industry experts working at the forefront of drug development and digital health share lessons learned delivering virtual trials during the Covid-19 pandemic. Catch up on a thought-leading discussion on how to mature the accelerated adoption of digital trials during lockdown
Webinars Back to resource centre 11 January 2023 Remote Cognitive Testing and Lessons Learned During Lockdown Traditionally, scientists assess cognition with thorough, but infrequent, testing sessions in a tightly controlled laboratory environment. In efforts to curb Covid-19 transmission rates, most researchers have postponed this form of face-to-face assessment. Between the longevity of this pandemic-driven lockdown, and the significant risk of
Webinars Back to resource centre 11 January 2023 Wearable Technology for High-Frequency Cognitive and Mood Assessments in Depression Despite the obvious advantages of conducting thorough assessments in highly controlled laboratory environments, the associated resource burden means that such lengthy assessments are out of the question for daily testing. The widespread adoption of smartphones and wearables makes monitoring symptoms in real
Webinars Back to resource centre 11 January 2023 Elderly patients in clinical trials: addressing the evidence-practice gap Despite carrying the largest burden of chronic diseases and taking more prescription medications than any other group, older adults are consistently under-represented in clinical trials. The complex, and therefore risky, treatment needs associated with older adults is often what makes sponsors hesitant to
Webinars Back to resource centre 11 January 2023 Future directions in eCOA: Innovations in high-frequency and automated voice-based testing As drug development programmes increasingly demand real-world data collection – are the current eCOA instruments fit for purpose? Which innovations will change the landscape, what are the challenges and how might we overcome them? In this webinar Chief Technology Officer at
Webinars Back to resource centre 11 January 2023 Pro-cognitive drug trial failures in schizophrenia: the need for cognitive screening? Despite a wealth of research, pharmaceutical companies have thus far been unsuccessful in their attempts to address cognitive impairment in schizophrenia. This begs the question: are these compounds truly ineffective or has trial methodology itself been a limiting factor in successfully
Webinars Back to resource centre 11 January 2023 Cognitive Safety: Satisfying Regulatory Requirements in a Competitive Landscape Common disease states, environmental toxins, certain medications and the aging process itself can all compromise the integrity of the BBB. Accordingly, both central nervous system (CNS) and non-CNS therapeutics (e.g. for cardiovascular disease, diabetes, cancer, pain) can present significant challenges for cognitive safety
Webinars Back to resource centre 11 January 2023 Digital Health: Optimizing Clinical Trials with Patient-Centric Technology Our expert speakers will navigate you through the new field of digital health in psychiatry, to conclude which technologies look to be most promising for optimizing clinical trials, and how to successfully operationalize these digital solutions. Key discussion points How digital health can streamline
Webinars Back to resource centre 11 January 2023 Early Alzheimer’s Disease: Finding the Right Patients for Clinical Trials and Beyond Despite considerable efforts by biopharmaceutical companies, late-stage trial failures have plagued the drug development process for targeting Alzheimer’s disease. So what’s the problem? Join Dr. Kenton Zavitz and Dr Robert Smith to discuss the issues surrounding the identification of patients for these early
Webinars Back to resource centre 11 January 2023 Schizophrenia Trials: Overcoming Methodological Challenges to Enhance Study Success This webinar was arranged to discuss the major unmet therapeutic need in schizophrenia: cognitive impairment. Despite best efforts, no drugs that have been approved for the amelioration of cognitive deficits in schizophrenia: are ineffective compounds or trial designs to blame? Join Dr Kiri
